retatrutide clinical trials germany Phase 2 Trial of for Obesity Retatrutide just delivered the first

Neuroprotective effect of curcumin-loaded RGD peptide-PEGylated nanoliposomes

FIBCD1 overexpression predicts poor prognosis in patients with hepatocellular carcinoma

Image Credit: siamionau pavel / Shutterstock Background Weight loss reduces obesity-related comorbidities but often leads to decreased bone mineral density (BMD) and increased bone turnover, raising fracture risk and mortality

GLP-1 medications are typically long-term or permanent treatments

The drugs monthly dosing and safety profile may also support multiple combination strategies in future trials

Nguyen, Jaw-Town Lin, Yao-Chun Hsu Clin Mol Hepatol 2024;30(1):98-108